AML patients Mipletamig combination enables rare pathway to transplant in a previously ineligible unfit patient No dose-limiting toxicities observed among evaluable patients; safety profile remains ...

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.

The clinical-stage biotechnology company announced an 85% remission rate in evaluable frontline AML patients treated with mipletamig in combination with standard-of-care venetoclax and azacitidine.

Aptevo Therapeutics shares bounced back from Tuesday's 52-week low, more than doubling Wednesday after the company reported favorable results for its lead drug candidate in an acute myeloid leukemia ...

AML patientsMipletamig combination enables rare pathway to transplant in a previously ineligible unfit patientNo dose-limiting toxicities observed among ...

Aptevo Therapeutics (NASDAQ: APVO) shares exploded in premarket trading, surging an incredible 123.4% to $6.30 after closing at just $2.82 the previous day. The dramatic spike comes after the ...